Amendment_1_Changes_Table.pdf
PDF 131 KB Posted
- Attached to
- Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
- Solicitation number
- BAA-23-100-SOL-00004
About this file
This document provides an amendment table for the Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA) solicitation number BAA-23-100-SOL-00004. The table outlines ten substantive changes made in Amendment 1, dated November 9, 2023, including updates to the overview information, background, technical objectives, pre-submission instructions, proposal instructions, evaluation criteria, and several areas of interest involving medical countermeasures and diagnostics. Key changes include adding a new area of interest for COVID-19 monoclonal antibody therapeutics, updating technical requirements for certain areas of interest, and suspending the area of interest for COVID-19 immune assays. The solicitation involves research and development of medical countermeasures and diagnostics and is issued by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.
View the file
Other files
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Change History Table: Original – Amendments (1) Amendment 1(Nov 9, 2023): BARDA BAA-23-100-SOL-00004 List of Changes:
Amendment 1 (Nov 9, 2023)
1. Updates to Overview Information –
• Updated Research and Development Opportunity Description
• Updated General Market Research (TechWatch Program),
• Updated Application Process,
• Updated Contract and Submission Information,
• Updated Electronic Portal Submission Instructions
2. Updates to Background
3. Updates to Part I: Development and Technical Objectives
4. Updates to Part IV: Pre-Submission Call and Quad Chart/Market Research Abstract Instructions (Stages 1 & 2)
• Updated Figure 1. BARDA BAA Process Flow Chart
• Updated Stage 1: Pre-submission Call with Technical POC
5. Updates to Part VI: Proposal Instructions (Stage 3)
• Updates to Stage 3: Proposal Precreation o Section M. Past Performance Information & o Vol. II, Attachment 10: Past Performance o Vol. II, Attachment 11: Reason for the Proposed Award Type
6. Updates to Part VII: Proposal Evaluation
7. Updates to Area of Interest #6: Burn and Blast Medical Countermeasures
• Updated TRL Requirement
8. Updates to Area of Interest #7: Diagnostics
• Updated AOI 7.1.3 Biothreat Agent Diagnostics: Filovirus Point-of-Care and Remote Settings
• Updated AOI 7.3.1 Influenza Home-Use Testing (for OTC or Prescription At-home)
• Updated AOI 7.3.3 Point-of-Care Multiplex Assay for Detection of Influenza Virus
9. Updates to Area of Interest #9: IEID Therapeutics
• Added new Area of Interest 9.4 COVID-19 Monoclonal Antibody Therapeutics for Treatment
• Updated Additional Assessment Factors for the Specific Topic AOIs
10. Suspend AOI #11: COVID-19 Immune Assay(s) Development and Implementation
| Change History Table: Original – Amendments (1) |
| Amendment 1(Nov 9, 2023): BARDA BAA-23-100-SOL-00004 List of Changes: |
File details come from the government source that posted it. Updated .